Optimisation of HIV care and service delivery: Doing more with less

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1860-1866

  Boyd, Mark A ^a,b   Cooper, David A ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Lowy Packer Building   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DECENTRALIZATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM SURVIVAL; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT TERM SURVIVAL; VIRUS LOAD; VIRUS REPLICATION;

EID: 84869509400     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61154-4     Document Type: Review

References (63)

1. WHO. Progress Report 2011. Global HIV/AIDS Response. http://whqlibdoc. who.int/publications/2011/9789241502986-eng.pdf (accessed March 20, 2012).
2. WHO, UNAIDS. The 3 by 5 initiative-treat 5 million people with HIV/AIDS by 2005. http://www.who.int/3by5/en/ (accessed March 20, 2012).
3. Political Declaration on HIV/AIDS: Intensifying Our Eff orts to Eliminate HIV/AIDS. United Nations General Assembly High Level Meeting on AIDS; New York, NY, USA; June 8-10, 2011. http://www.unaids.org/en/aboutunaids/ unitednationsdeclarationsandgoals/2011highlevelmeetingonaids/ (accessed March 22, 2012).
4. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
5. Alberts B. Science breakthroughs. Science 2011; 334: 1604.
6. The Kaiser Family Foundation and UNAIDS. Funding the response to AIDS in low- and middle-income countries: international assistance from donor governments in 2010. http://www.unaids.org/en/media/unaids/contentassets/ documents/document/2011/08/20110816-Report-Financing-the-Response-to-AIDS.pdf (accessed Feb 2, 2012).
7. Institute for Health Metrics and Evaluation. Financing global health 2011: continued growth as MDG deadline approaches. http://www. healthmetricsandevaluation.org/publications/policy-report/financing-global- health-2011-continued-growth-mdg-deadlineapproaches (accessed June 17, 2012).
8. UN General Assembly. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. http://www.un.org/ga/search/view-doc.asp?symbol=A/66/L.1 (accessed June 17, 2012).
9. Leach-Kemon K, Chou DP, Schneider MT, et al. The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff (Millwood) 2012; 31: 228-35.
10. The Global Fund. The Global Fund is alive and well, But Global Health Progress is in Peril. http://www.theglobalfund.org/en/mediacenter/announcements/ 2011-12-01-The-Global-Fund-is-alive-and-well-But-Global-Health-Progress-is-in- Peril-by-Simon-Bland-the-Chair-of-the-Board-of-the-Global-Fund/(accessed April 6, 2012).
11. The Global Fund. Global Fund Forecasts $1·6 billion in Available Funds for 2012-2014. http://www.theglobalfund.org/en/mediacenter/ pressreleases/2012-05-09-Global-Fund-Forecasts-USD-1-6-billion-in-Available- Funds-for-2012-2014-Major-Shift-Reflects-Strategic-Choices-by-Board-Renewed- Confidence/ (accessed May 25, 2012).
12. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-64.
13. Boyd M.A. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009; 4: 194-99.
14. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007; 370: 12-14.
15. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48: 484-88.
16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
17. When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-63.
18. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
19. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171: 1560-69.
20. The HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154: 509-15.
21. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44.
22. Department of Health and Human Services, USA. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/guidelines/html/1/adult-andadolescent-treatment- guidelines/0/ (accessed April 5, 2012).
23. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-65.
24. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: recommendations for a public health approach 2010 revision. http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf (accessed March 23, 2012).
25. Koenig SP, Bang H, Severe P, et al. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti CEPAC-International Investigators. PLoS Med 2011; 8: e1001095.
26. CEPAC-International Investigators. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010; 7: e1000382.
27. Humphreys EH, Chang LW, Harris J. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2010; 6: CD006517.
28. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49: 454-62.
29. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-34.
30. Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009; 14: 1005-09.
31. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-52.
32. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. 2002. http://www.who.int/hiv/pub/prev-care/en/ScalingUp-E.pdf (accessed March 13, 2012).
33. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2006. http://whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf (accessed March 13, 2012).
34. WHO/UNAIDS. The treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. http://www.who.int/hiv/pub/arv/treatment/ en/index.html (accessed May 19, 2012).
35. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr 2010; 55: 1-7.
36. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings. J Acquir Immune Defic Syndr 2011; 58: 141-47.
37. Omega Diagnostics Group PLC announces launch of VISITECT® CD4 point-of-care test. http://www.free-press-release.com/newsomega-diagnostics- group-plc-announces-launch-of-visitect-cd4-point-of-care-test-1340282993.html (accessed July 11, 2012).
38. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-31.
39. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.
40. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 3, 2011. Abstract 44.
41. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825-33.
42. Chang LW, Harris J, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev 2010; 4: CD008494.
43. Nuesch R, Srasuebkul P, Ananworanich J, et al. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006; 58: 637-44.
44. Taiwo B, Yanik E, Napravnik S, et al. Laboratory abnormalities following initiation of modern ART in the US, 2000-2010 among the CNICS cohort. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; March 5-8, 2012. Abstract 633.
45. Gogtay JA. The impact of generic antiviral drugs. IDrugs 2007; 10: 881-84.
46. Mécins Sans Frontiès. Untangling the Web of Antiretroviral Price Reductions http://utw.msfaccess.org/ (accessed March 23, 2012).
47. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C; for the participants of The Conference on Antiretroviral Drug Optimization. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12: 550-60.
48. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8: 679-88.
49. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10: 301-07.
50. Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125-33.
51. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25: 1737-45.
52. Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 2012; 56: 1427-33.
53. Jackson A, Hill A, Puls R, et al. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.J Antimicrob Chemother 2011; 66: 635-40.
54. WHO HIV/AIDS Programme. Short-Term Priorities For Antiretroviral Drug Optimization. http://www.who.int/hiv/pub/arv/short-term-priorities/en/index.html (accessed Jan 26, 2012).
55. WHO HIV/AIDS Programme. Diagnosis, Treatment Initiation & WHO Expert Meeting on Short-Term HIV Diagnosis, Treatment Initiation & Monitoring Technologies and Approaches. http://whqlibdoc.who.int/publications/2012/ 9789241503556-eng.pdf (accessed May 19, 2012).
56. Crisp N. Turning the world upside down: the search for global health in the 21st century. London: Royal Society for Medicine Press, 2010.
57. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376: 33-40.
58. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 2009; 374: 2080-89.
59. Long L, Brennan A, Fox MP, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 2011; 8: e1001055.
60. Brennan AT, Long L, Maskew M, et al. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS 2011; 25: 2027-36.
61. WHO. Stop TB Partnership. TB/HIV Working Group. http://www.stoptb.org/wg/ tb-hiv/about.asp (accessed March 26, 2012).
62. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis 2010; 50 (suppl 3): S238-44.
63. Cooper DA, Cahn P, Lewin S, et al. The Sydney Declaration: a call to scale up research. Lancet 2007; 370: 7-8.